These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 26866300)

  • 1. Liposomal adjuvants for human vaccines.
    Alving CR; Beck Z; Matyas GR; Rao M
    Expert Opin Drug Deliv; 2016 Jun; 13(6):807-16. PubMed ID: 26866300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21.
    Beck Z; Matyas GR; Jalah R; Rao M; Polonis VR; Alving CR
    Vaccine; 2015 Oct; 33(42):5578-5587. PubMed ID: 26372857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Army Liposome Formulation (ALF) family of vaccine adjuvants.
    Alving CR; Peachman KK; Matyas GR; Rao M; Beck Z
    Expert Rev Vaccines; 2020 Mar; 19(3):279-292. PubMed ID: 32228108
    [No Abstract]   [Full Text] [Related]  

  • 4. Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21.
    Alving CR; Rao M; Matyas GR
    Front Immunol; 2023; 14():1102524. PubMed ID: 36761767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant system AS01: from mode of action to effective vaccines.
    Roman F; Burny W; Ceregido MA; Laupèze B; Temmerman ST; Warter L; Coccia M
    Expert Rev Vaccines; 2024; 23(1):715-729. PubMed ID: 39042099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.
    Alving CR; Rao M; Steers NJ; Matyas GR; Mayorov AV
    Expert Rev Vaccines; 2012 Jun; 11(6):733-44. PubMed ID: 22873129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status.
    Korsholm KS; Andersen PL; Christensen D
    Expert Rev Vaccines; 2012 May; 11(5):561-77. PubMed ID: 22827242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.
    Beck Z; Torres OB; Matyas GR; Lanar DE; Alving CR
    J Control Release; 2018 Apr; 275():12-19. PubMed ID: 29432824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine approaches for antigen capture by liposomes.
    Zhou S; Luo Y; Lovell JF
    Expert Rev Vaccines; 2023; 22(1):1022-1040. PubMed ID: 37878481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Composition and mode of action of adjuvants in licensed viral vaccines].
    Wagner R; Hildt E
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Apr; 62(4):462-471. PubMed ID: 30830257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influenza virosomes as vaccine adjuvant and carrier system.
    Moser C; Müller M; Kaeser MD; Weydemann U; Amacker M
    Expert Rev Vaccines; 2013 Jul; 12(7):779-91. PubMed ID: 23885823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants.
    Alving CR
    Immunobiology; 1993 Apr; 187(3-5):430-46. PubMed ID: 8330907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery.
    Muderhwa JM; Matyas GR; Spitler LE; Alving CR
    J Pharm Sci; 1999 Dec; 88(12):1332-9. PubMed ID: 10585231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant and antigen delivery properties of virosomes.
    Glück R; Burri KG; Metcalfe I
    Curr Drug Deliv; 2005 Oct; 2(4):395-400. PubMed ID: 16305442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Genito CJ; Beck Z; Phares TW; Kalle F; Limbach KJ; Stefaniak ME; Patterson NB; Bergmann-Leitner ES; Waters NC; Matyas GR; Alving CR; Dutta S
    Vaccine; 2017 Jul; 35(31):3865-3874. PubMed ID: 28596090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition.
    Singh P; Beck Z; Matyas GR; Alving CR
    J Liposome Res; 2019 Sep; 29(3):247-250. PubMed ID: 30350748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.